Mesenchymal stem cells alleviate TNBS-induced colitis by modulating inflammatory and autoimmune responses

Figure 3 Therapeutic efficacy of bone marrow mesenchymal stem cells treatment. A: Colon length at day 3; B: Macroscopic colonic damage at day 3; C: Histopathologic colonic damage by hematoxylin and eosin staining at day 3 (× 100); D-F: Clinical evolutions were monitored by body weight changes, colitis score and survival; G) Colon length changes; H: Histopathology score changes. ^aP < 0.05, ^bP < 0.01 vs control; ^cP < 0.05, ^dP < 0.01 vs TNBS-PBS. TNBS-MSC: Trinitrobenzene sulfonic acid-mesenchymal stem cells; TNBS-PBS: Trinitrobenzene sulfonic acid-phosphate-buffered saline.